Analyst Ratings For Clovis Oncology Inc (NASDAQ:CLVS)
Today, SunTrust Banks lowered its price target on Clovis Oncology Inc (NASDAQ:CLVS) to $28.00 per share.
There are 8 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Clovis Oncology Inc (NASDAQ:CLVS) is Buy with a consensus target price of $42.75 per share, a potential 82.07% upside.
Some recent analyst ratings include
- 4/14/2019-Clovis Oncology Inc (NASDAQ:CLVS) had its Neutral rating reiterated by Piper Jaffray Companies with a $21.00 price target
- 4/7/2019-Clovis Oncology Inc (NASDAQ:CLVS) had its Hold rating reiterated by JPMorgan Chase & Co.
- 12/11/2018-Clovis Oncology Inc (NASDAQ:CLVS) had its Buy rating reiterated by Gabelli
- 12/4/2018-Clovis Oncology Inc (NASDAQ:CLVS) gets upgraded to Outperform by Leerink Swann
- On 3/20/2019 Lindsey Rolfe, Insider, sold 1,729 with an average share price of $26.13 per share and the total transaction amounting to $45,178.77.
- On 3/14/2019 James C Blair, Director, sold 17,056 with an average share price of $27.79 per share and the total transaction amounting to $473,986.24.
- On 3/5/2019 Lindsey Rolfe, Insider, sold 1,731 with an average share price of $29.29 per share and the total transaction amounting to $50,700.99.
- On 2/27/2019 Daniel W Muehl, Insider, sold 266 with an average share price of $25.90 per share and the total transaction amounting to $6,889.40.
- On 12/20/2018 Lindsey Rolfe, Insider, sold 1,728 with an average share price of $17.72 per share and the total transaction amounting to $30,620.16.
- On 12/4/2018 Lindsey Rolfe, Insider, sold 284 with an average share price of $21.23 per share and the total transaction amounting to $6,029.32.
- On 4/9/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.02 per share and the total transaction amounting to $270,090.00.
About Clovis Oncology Inc (NASDAQ:CLVS)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Recent Trading Activity for Clovis Oncology Inc (NASDAQ:CLVS)
Shares of Clovis Oncology Inc closed the previous trading session at 23,48 −0,28 1,18 % with 23.11 shares trading hands.